Adult Normative Performance of the Quotient ADHD System

NCT ID: NCT01308450

Last Updated: 2013-11-27

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 300 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2011-03-31
• Study Completion Date: 2011-06-30

Brief Summary

This study is being conducted to enhance and extend the clinical utility of the Quotient® ADHD System Adolescent and Adult Version Test by adding large numbers of well-screened controls to the existing Quotient® ADHD System database of adolescents and adults (ages 15-55).

Detailed Description

This study consists of one study visit. Subjects will be recruited using the clinic's relevant patient population. A "Study Recruitment Flyer" will also be posted in various clinic locations (Attachment BBD0111-1). Interested volunteers will participate in an initial screening, which may be done by telephone or in person that will be conducted by the clinic's research staff. Upon preliminary confirmation that the subject meets all inclusion criteria and does not meet any exclusion criteria, an appointment will be scheduled for the study visit.

At the study visit, study will be explained in detail. Adults will be asked to provide written informed consent, parents/guardians of individuals <18 year old will provide written informed consent and minor individual's will provide written assent, prior to any study procedure being performed.

Following consent, a medical history, including current medications the subject is taking, will be obtained. Subjects will complete standard self assessment questionnaires to screen for presence of mental health issues including ADHD, anxiety disorder, depressive disorder or bipolar disorder using the ADHD Self Rating Scale (ASRS), Zung Self-Rated Anxiety Scale (SAS), Zung Self-Rated Depression Scale (SDS), and Mood Disorder Questionnaire (MDQ).

Subjects will not be excluded from the study based on responses to the mental health questionnaires, but results will be considered in the analysis of results.

The subjects will take the 20-minute Quotient® ADHD System Test for Adolescent and Adult assessment.

Subject's assessed to be Non-ADHD will be eligible to have their Quotient tests added to the Quotient Adolescent and Adult Normative Database.

Study Enrollment:

200 Normal control subjects with oversampling of 10%. Total enrollment is expected to be 220.

Study Population:

Male and female subjects from age 15 through 55 years of age. Optimally, there will be approximately 25 subjects per age and gender category but enrollment will not be restricted or limited to these desired categorical goals.

Age Ranges Males Females 15-25 25 25 26-35 25 25 36-45 25 25 46-55 25 25

Conditions

ADHD

Keywords

ADHD Normative Control Group

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: CROSS_SECTIONAL

Study Groups

Single Arm, Non ADHD Control Group

Single site, single visit study. Subjects will be administered Standard Rating Scales (Defined) and the Quotient ADHD System Test (Adolescent and Adult Version). Subject's assessed to be Non-ADHD will be eligible to have their Quotient tests added to the Quotient Adolescent and Adult Normative Database.

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

1. Male or Female

2. Ages 15 to 55

3. Un-medicated with medications known to affect ADHD or cognitive functioning

4. Report of good physical health

5. Able to understand test instructions and comply with testing

6. Willing to give written informed consent and/or assent

Exclusion Criteria

1. History of diagnosis of ADHD

2. History of known neurological disease or insult (e.g., head trauma with LOC, skull fracture, past or present migraine headaches, seizure disorders)

3. Major Medical Disorders

4. Past/present alcohol or substance abuse or dependence

5. Current or past DSM-IV disorder, screened by the computerized SCID I & II, and reviewed by investigator

6. Any major medical or neurological condition that could affect motor activity or attention (e.g. Parkinson's, MS, dementia)

7. Currently ill with cold/flu/infections which may compromise their ability to perform the computer task

• Minimum Eligible Age: 15 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

BioBehavioral Diagnostics Company

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

The Focus Center

Clinton, Utah, United States

Countries

United States

References

Pivonello R, Muscogiuri G, Holder G, Paul M, Sarp S, Lesogor A, Jordaan P, Eisinger J, Colao A. Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies. Endocrine. 2018 Apr;60(1):65-72. doi: 10.1007/s12020-017-1448-5. Epub 2017 Nov 7.

Reference Type: DERIVED

PMID: 29116540 (View on PubMed)

Other Identifiers

BBD0111

Identifier Type: OTHER

Identifier Source: secondary_id

BBD0111

Identifier Type: -

Identifier Source: org_study_id